Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Bundschuh, C.
Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer Patients
Humanmedizin; [ Diplomarbeit ] Graz Medical University; 2018. pp. 107
[OPEN ACCESS]
FullText
- Autor*innen der Med Uni Graz:
- Betreuer*innen:
- Heinemann Akos
- Kargl Julia
- Altmetrics:
- Abstract:
- This diploma thesis with the title ‘Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer Patients’ deals with the topic of lung cancers, focused on non-small cell lung cancers (NSCLCs). Therefore, their incidence numbers, the anatomical and histological characteristics of the pulmonary systems, risk factors for the development of lung cancers, classification and staging of NSCLCs, diagnostic and therapeutic approaches, with the emphasis on immunotherapeutics were investigated. This thesis focuses on a systematic review of the recent developments and currently ongoing clinical trials in the field of immune checkpoint inhibitors. The literature researched for this topic includes books, journals, and current treatment guidelines. For this purpose, the databases PubMed, ClinicalTrials and UpToDate, as well as the guidelines of the ICDO, TNM, and ESMO, were used. If possible, current literature (not older than 5 years) was used, especially in the immunotherapy chapter. The results of this thesis include the systematic processing of the anatomical and histological bases of the pulmonary system, the current risk factors, systematic classifications, diagnostic and therapeutic guidelines for lung cancers, in particular, NSCLCs. The chapter on immunotherapy provides a brief outline of the history of immunotherapy and an overview of the different types of immunotherapy. The systematic review deals with immune checkpoint inhibitors. This chapter includes a presentation of the already Food and Drug Administration (FDA) approved substances, as well as a delineation of (early) clinical trials. Due to advances in immunotherapy research, which resulted in an approval of various immunotherapeutic agents, such as PD-L1 inhibitors, immunotherapy has already become an integral part of the recommended treatment plan for certain indications. In the future, immune checkpoint inhibitors are expected to play an increasingly important role as part of combination therapies in the treatment of NSCLC (in addition to established surgical, chemo- and radiotherapy treatment plans).